Biogen’s Aduhelm should be more limited to a certain group of patients, some Alzheimer’s experts argue. The controversial drug, which was recently approved by the Food and Drug Administration, currently doesn’t have many limitations on how it should be prescribed. (The New York Times)
Dr. Anthony Fauci warns that the COVID-19 delta variant is currently the “greatest threat” to the U.S. effort to curb the pandemic. The U.S. may not hit its goal of getting 70% of Americans vaccinated by July 4th, the Biden administration said Tuesday. (CNBC Weekly)
Senate Finance Chair Ron Wyden outlined a new drug pricing proposal with the hopes of jump-starting discussions on the issue, as moderate Democrats have stalled. The proposal includes giving Medicare the power to negotiate with pharma companies. (Politico)
A new research collaboration aims to create protocols to help vet digital health data from wearables. It’s part of a trend shift since the COVID-19 pandemic in which companies are moving towards decentralized trials, where digital devices collect data from home. (STAT)
Merck’s Keytruda achieved its primary endpoints in a Phase III KEYNOTE-826 study, the company said Tuesday. The cancer drug, in addition to chemotherapy, extended the lives of patients with first-line cervical cancer compared to those on a placebo. (Endpoints News)
